Chief Medical Officer · Trevi Therapeutics, Inc. (TRVI)

David Clark

A named executive officer of Trevi Therapeutics in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$610,638

Salary $479,038Stock awards $0Bonus $131,600

FY2022: $580,781

3rd of 3 named executive officers at Trevi Therapeutics by FY2023 total.

3 named officers on file for Trevi Therapeutics, FY2023

David Clark’s pay file — $29

  • 2 fiscal years of pay, line by line
  • TRVI’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Trevi Therapeutics’s whole pay program stands against its peers

  • Trevi Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TRVI→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A).

Free

Get David Clark’s full pay file as a PDF — free

More than this page: up to 10 years of David’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

David Clark compensation by year

Trevi Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Trevi Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$54,231$479,038
Bonus$0$131,600
Stock awards$0$0
Option awards$526,550$0
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$0$0
Total$580,781$610,638

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Trevi Therapeutics, Inc. DEF 14A filed April 26, 2024, accession 0000950170-24-049234, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Trevi Therapeutics, Inc. filed document, accession 0000950170-24-049234. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

$581K
$611K
FY22
FY23
SalaryBonusOption awards

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option218,750—$2.02

Per the Outstanding Equity Awards at Fiscal Year-End table in Trevi Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Trevi Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Jennifer GoodPresident and Chief Executive Officer$1,687,298
Thomas SciasciaChief Scientific Officer$977,125
David Clark · this pageChief Medical Officer$610,638

The full Trevi Therapeutics compensation record

free company brief

This page is one person within Trevi Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Trevi Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Trevi Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

David Clark's compensation dossier · One-time report. No refunds.